טקסוטר

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Disponível em:

SANOFI - AVENTIS ISRAEL LTD

Código ATC:

L01CD02

Forma farmacêutica:

CONCENTRATE FOR SOLUTION FOR INFUSION

Via de administração:

I.V

Fabricado por:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Grupo terapêutico:

DOCETAXEL

Indicações terapêuticas:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Data de autorização:

2012-11-01